Summary/Conclusion
For patients with locally advanced primary or recurrent gynecologic cancers, prognosis is poor. Doses of EBRT required to treat either gross or microscopic disease in patients previously irradiated or treated surgically exceed doses that are tolerated by normal anatomic structures …
Read MoreSummary/Conclusion
Long-term survival is possible with combined modality therapy including IOERT for advanced cervical cancer.
Read MoreSummary/Conclusion
Combined modality therapy with EBRT, surgery and IOERT is an option for the treatment of localized recurrent ovarian cancer, with acceptable rates of in-field failure and toxicity. Durable disease control is possible in select women treated with this regimen.
Read More